Autologous T cells engineered with a CD19-specific chimeric antigen receptor incorporating CD28 costimulation and a CD3ζ signaling domain. Binding to CD19 on malignant B cells triggers T‑cell activation, expansion, cytokine release, and cytotoxic killing, leading to depletion of CD19+ cells. An EGFRt tag allows cell tracking and potential ablation with cetuximab. Administered intracerebroventricularly to target CD19+ lymphoma cells in the CNS.